BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Completed · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

Key facts

Study ID

NCT01354431

Run by

Bristol-Myers Squibb

People needed

168

Starts

2011-05-31

Expected to finish

2021-04-15

Last updated by the study team

2022-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component
• Previous treatment with at least one anti-angiogenic agent
• Progressed within 6 months of study enrollment
• Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease
• Must have available tumor tissue for submission
• Subjects must also meet various laboratory parameters for inclusion

You may not qualify if…

• Subjects with any active autoimmune disease or a history of known autoimmune disease
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• UCSD Moores Cancer Center — La Jolla, California, United States
• Ucla — Los Angeles, California, United States
• Samuel Oschin Comprehensive Cancer Inst. — Los Angeles, California, United States
• Stanford Cancer Center — Stanford, California, United States
• University Of Colorado — Aurora, Colorado, United States
• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Northwestern University Feinberg School Of Medicine — Chicago, Illinois, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Indiana University Health Melvin And Bren Simon Cancer Center — Indianapolis, Indiana, United States
• University Of Kansas Medical Center — Kansas City, Kansas, United States
• University Of Maryland — Baltimore, Maryland, United States
• The Bunting-Blaustein Cancer Research Building — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Ctr. — Boston, Massachusetts, United States
• University Of Michigan Medical Center — Ann Arbor, Michigan, United States
• Wayne State University — Detroit, Michigan, United States
• Masonic Cancer Ctr, University Of Minnesota — Minneapolis, Minnesota, United States
• North Mississippi Hematology And Oncology Associates, Ltd — Tupelo, Mississippi, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• St. Luke'S Roosevelt Hospital Center — New York, New York, United States
• Mount Sinai Medical Center — New York, New York, United States
• Memorial Sloan Kettering Nassau — New York, New York, United States
• Weill Cornell Medical College — New York, New York, United States
• Blumenthal Cancer Center — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.